An active targeting drug delivery system encapsulated with vincristine: folic acid-PEGliposomal vincristine (FA-PEG-LS/VCR) was successfully developed to enhance the therapeutic efficacy and improve the multidrug resistance (MDR) to vincristine.
INTRODUCTION
MDR is a major cause of the failure of cancer treatment 1 . The most common underlying mechanism of MDR has been correlated with overexpression of P-glycoproten (P-gp), leading to the efflux of many anticancer drugs with consequent drug insensitivity 2 . Herein, we prepared a novel FA-PEG-LS/VCR for targeted therapy of MDR cancer 3 .
EXPERIMENTAL METHODS 1. Targeting ability study of FA-PEG-LS in vitro and in vivo
The KBv200 cells were incubated with FA-PEG-LS/FAM, PEG-LS/FAM or free FAM in culture medium, washed with PBS and were trypsinized and centrifuged, washed, resuspended in PBS and analyzed using a flow cytometer for quantitative analysis.
FA-PEG-LS/DiR were given by tail vein injection on KBv200 tumor bearing mice, and PEG-LS/DiR was adopted as control. At predetermined times post-injection, the mice were anesthetized and detected in whole body using an in vivo imaging system.
Cytotoxicity study of FA-PEG-LS/VCR in vitro
The in vitro antitumor activity of drugloaded liposomes and free drugs were determined by MTT assay. The treatments included FA-PEG-LS/VCR, PEG-LS/VCR, free VCR and control group. The concentrations of VCR used in the treatments were ranging from 6 x 10 -5 nM to 300 µM. Results were presented as cell inhibitory rate and IC 50 values. The cytotoxicity of drug-loaded liposomes was expressed as IC 50 values, defined as the drug concentration required to inhibit growth by 50% relative to controls, which were calculated using nonlinear regression analysis.
Tumor growth inhibition efficacy study of FA-PEG-LS/VCR
On day 0 (14 days after tumor cell implantation), the tumors reached sizes of 10-20 mm 3 , at which time the mice received one of the following treatments: high dosage FAconjugated liposomal VCR (6 mg/kg, FA-PEG-LS/VCR, Group I), low dosage FA-conjugated liposomal VCR (2 mg/kg, FA-PEG-LS/VCR, Group II), liposomal VCR (2 mg/kg, PEG-LS/VCR, Group III), free VCR (2 mg/kg, Group IV) and physiological saline (Group V). The drug was given by tail vein injection on every 4 th day for three doses (days 0, 4 and 8). Tumor size was measured on every second day, and animal survival was monitored daily. Tumor size was calculated using the equation: volume = maximal diameter x (minimum diameter) 2 
Cytotoxicity study of FA-PEG-LS/VCR in vitro
The cytotoxicities of various VCR formulations were compared on KBv200 cells. VCR concentrations leading to IC 50 were determined from concentration-dependent cell viability curves (Figure 2) . Figure 2 . Concentration-dependent cell viability curve of various VCR formulations against KBv200 in vitro by MTT assay (n = 6).
Tumor growth inhibition efficacy study of FA-PEG-LS/VCR
The tumor volume is a reliable indicator to evaluate the anti-tumor efficacy of the drug delivery system on the solid tumor models. As showed in Fig. 89 , the tumor inhibition rate for free VCR, PEG-LS/VCR, FA-PEG-LS/VCR (2 mg/kg), FA-PEG-LS/VCR (6 mg/kg) is 42.60%, 44.25%, 60.11%, 74.75% (in volume), respectively and 39.27%, 44.01%, 59.98%, 69.55% (in weight) respectively.
Results indicated that: 1. Folic acid modification significantly strengthened the antitumor efficacy of the PEGylated liposomal VCR; 2. PEGylation significantly strengthened the anti-tumor efficacy of the cytotoxic agents; 3. Folic acid-conjugated PEGylated liposomal VCR showed dosage-dependent characteristics (Figure 3) . 
CONCLUSION
FA-PEG-LS/VCR, a new liposomal drug delivery system (DDS) for MDR cancer therapy, was constructed successfully. It showed great targeting ability in vitro and in vivo. Its targeting efficiency in vitro was as 50-fold as the one of free VCR on KBv200 (multidrug resistant variant); meanwhile, its targeting efficiency in vivo was as 1.5-fold as the one of PEG-LS/VCR. We subsequently verify its advantages in inhibiting the tumor growth compared with control groups in vitro and in vivo. Herein, this DDS proves itself to a wide potential clinical application with more safe and effective potency in the fight against MDR cancer.
